AMO's Healon D latex-free viscoelastic has been granted premarket approval by the FDA. The clear dispersive ophthalmic viscosurgical device (OVD) is designed to be used during phacoemulsification, intraocular lens (IOL) implantation, keratoplasty and glaucoma filtration surgery.
AMO’s Healon D latex-free viscoelastic has been granted premarket approval by the FDA. The clear dispersive ophthalmic viscosurgical device (OVD) is designed to be used during phacoemulsification, intraocular lens (IOL) implantation, keratoplasty and glaucoma filtration surgery.
Healon D has low viscosity and a low molecular weight, allowing it to provide lubrication for IOL insertion and to remain coating the cornea throughout surgery, thereby providing endothelial cell protection. Healon D will be available in dual-packs with either standard Healon, or with Healon GV, an existing AMO OVD, which has a high molecular weight and a high viscosity to allow increased expansion of the anterior chamber.
The packs containing Healon D will be available in the US before the end of the year.
AAO 2024: Detail outlined for Artificial Intelligence Innovation Center at Wilmer Eye Institute
October 24th 2024During a conversation at the American Academy of Ophthalmology annual meeting in Chicago, T.Y. Alvin Liu, MD, discussed plans for the James P. Gills Jr, MD, & Heather Gills Artificial Intelligence Innovation Center at the Wilmer Eye Institute at Johns Hopkins Medicine.